Biotech company Crucell today announced that it has booked ‘positive results’ in the development of a vaccine against rabies. Crucell has tested the vaccine on volunteers in India and the US.

Investors reacted enthusiastically to the news and the company’s share price rose 5% on the Amsterdam exchange on Friday morning, reported ANP news service.
Crucell estimates that the market for the rabies vaccine is worth over €300m.
Around 10 million people worldwide are treated for rabies every year and up to 70,000 die from the disease, mainly in Asia, says Crucell.